Micreos News - Updates

• 01/03/2023

  
  • Updates

  Micreos spins off to focus on innovative pharmaceuticals to transform patient care in the treatment of chronic and acute bacterial infections.

  Since its founding in 2005, Micreos has become a world leading developer of endolysin and phage technology, enabling the targeted killing of only unwanted bacteria while protecting the rest of the Microbiome.

  Read More

• 18/10/2022

  
  • Updates

  Micreos ramps up the global fight against antimicrobial resistance and builds world-class antimicrobial vector engineering team.

  Dr. Matthew Dunne, Dr. Samuel Kilcher and Dr. Anja Keller join us from the Swiss Federal Institute of Technology (ETH Zurich), with the goal of developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.

  Read More